Amphastar P Asset Resilience Ratio
Amphastar P asset resilience ratio. Amphastar P (AMPH) has an Asset Resilience Ratio of 3.81% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Amphastar P defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Amphastar P (2012–2025)
Asset resilience ratio of Amphastar P from 2012 to 2025. This chart shows how Amphastar P's Asset Resilience Ratio has changed over time. Read Amphastar P debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Amphastar P's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see AMPH current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $66.51 Million | 3.81% |
| Total Liquid Assets | $66.51 Million | 3.81% |
Asset Resilience Insights
- Limited Liquidity: Amphastar P maintains only 3.81% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Amphastar P Industry Peers by Asset Resilience Ratio
Compare Amphastar P's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Amphastar P Asset Resilience Ratio by Year (2012–2025)
Amphastar P asset resilience ratio by year from 2012 to 2025. The table below shows the annual Asset Resilience Ratio data for Amphastar P.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 6.91% | $112.64 Million | $1.63 Billion | +2.47pp |
| 2024-12-31 | 4.44% | $70.04 Million | $1.58 Billion | -3.00pp |
| 2023-12-31 | 7.44% | $112.51 Million | $1.51 Billion | +4.79pp |
| 2022-12-31 | 2.65% | $19.66 Million | $741.99 Million | +1.11pp |
| 2021-12-31 | 1.54% | $10.32 Million | $671.53 Million | -0.52pp |
| 2020-12-31 | 2.06% | $12.98 Million | $631.24 Million | -0.32pp |
| 2019-12-31 | 2.38% | $13.96 Million | $586.97 Million | +1.83pp |
| 2018-12-31 | 0.55% | $2.83 Million | $513.56 Million | -0.03pp |
| 2017-12-31 | 0.58% | $2.63 Million | $454.67 Million | +0.46pp |
| 2016-12-31 | 0.12% | $527.00K | $427.74 Million | -0.21pp |
| 2015-12-31 | 0.33% | $1.28 Million | $390.14 Million | -0.05pp |
| 2014-12-31 | 0.38% | $1.50 Million | $389.37 Million | -0.01pp |
| 2013-12-31 | 0.39% | $1.32 Million | $338.75 Million | -0.20pp |
| 2012-12-31 | 0.59% | $1.89 Million | $317.48 Million | -- |
About Amphastar P
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mi… Read more